Bayesian Capital Management’s NovoCure NVCR Stock Holding History

Bayesian Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-39,716	Closed	-$641K	–	949
2023 Q3	$641K	Buy	+39,716	New	+$1.15M	0.07%	313
2023 Q2	–	Sell	-11,200	Closed	-$674K	–	984
2023 Q1	$674K	Buy	+11,200	New	+$895K	0.08%	314
2022 Q3	–	Sell	-4,850	Closed	-$337K	–	927
2022 Q2	$337K	Buy	+4,850	New	+$365K	0.06%	436
2021 Q2	–	Sell	-2,894	Closed	-$383K	–	577
2021 Q1	$383K	Buy	2,894 +435	+18%	+$68.8K	0.09%	293
2020 Q4	$426K	Buy	+2,459	New	+$336K	0.11%	239
2020 Q1	–	Sell	-2,700	Closed	-$228K	–	918
2019 Q4	$228K	Buy	+2,700	New	+$218K	0.04%	501
2017 Q1	–	Sell	-10,189	Closed	-$80K	–	617
2016 Q4	$80K	Buy	+10,189	New	+$82K	0.02%	567

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bayesian Capital Management's NVCR Position: Q4 2023 in Review

Bayesian Capital Management sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 39,716 shares — an estimated $641K sold.

Bayesian Capital Management first reported a position in NVCR in Q4 2016 and held it in 7 quarters. The position peaked at $674K in Q1 2023. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

Bayesian Capital Management reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 39,716 NovoCure shares in Q4 2023, an estimated $641K.
Bayesian Capital Management first reported a position in NovoCure in Q4 2016 and held it in 7 quarters.
Bayesian Capital Management's NovoCure position peaked at $674K in Q1 2023.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.